VistaGen Therapeutics, Inc.
VTGN
$0.24
-$0.01-2.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 504.92% | 3,200.00% | 29.49% | 40.98% | 190.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 504.92% | 3,200.00% | 29.49% | 40.98% | 190.48% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 504.92% | 3,200.00% | 29.49% | 40.98% | 190.48% |
| SG&A Expenses | -10.34% | -3.53% | 38.95% | 4.79% | -4.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.63% | 18.66% | 29.28% | 40.95% | 31.38% |
| Operating Income | 15.54% | -15.33% | -29.27% | -40.95% | -30.28% |
| Income Before Tax | 13.68% | -19.30% | -34.14% | -49.89% | -40.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.68% | -19.35% | -34.14% | -49.81% | -40.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.68% | -19.35% | -34.14% | -49.81% | -40.64% |
| EBIT | 15.54% | -15.33% | -29.27% | -40.95% | -30.28% |
| EBITDA | 15.66% | -15.29% | -29.25% | -40.94% | -30.31% |
| EPS Basic | 35.86% | 11.00% | 2.44% | -28.36% | -34.79% |
| Normalized Basic EPS | 35.87% | 11.04% | 2.44% | -28.45% | -34.81% |
| EPS Diluted | 35.86% | 11.00% | 2.44% | -28.36% | -34.79% |
| Normalized Diluted EPS | 35.87% | 11.04% | 2.44% | -28.45% | -34.81% |
| Average Basic Shares Outstanding | 34.60% | 34.13% | 37.52% | 16.70% | 4.34% |
| Average Diluted Shares Outstanding | 34.60% | 34.13% | 37.52% | 16.70% | 4.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |